Literature DB >> 17485642

ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease.

A Di Fonzo1, H F Chien, M Socal, S Giraudo, C Tassorelli, G Iliceto, G Fabbrini, R Marconi, E Fincati, G Abbruzzese, P Marini, F Squitieri, M W Horstink, P Montagna, A Dalla Libera, F Stocchi, S Goldwurm, J J Ferreira, G Meco, E Martignoni, L Lopiano, L B Jardim, B A Oostra, E R Barbosa, V Bonifati.   

Abstract

OBJECTIVE: To assess the prevalence, nature, and associated phenotypes of ATP13A2 gene mutations among patients with juvenile parkinsonism (onset <21 years) or young onset (between 21 and 40 years) Parkinson disease (YOPD).
METHODS: We studied 46 patients, mostly from Italy or Brazil, including 11 with juvenile parkinsonism and 35 with YOPD. Thirty-three cases were sporadic and 13 had positive family history compatible with autosomal recessive inheritance. Forty-two had only parkinsonian signs, while four (all juvenile-onset) had multisystemic involvement. The whole ATP13A2 coding region (29 exons) and exon-intron boundaries were sequenced from genomic DNA.
RESULTS: A novel homozygous missense mutation (Gly504Arg) was identified in one sporadic case from Brazil with juvenile parkinsonism. This patient had symptoms onset at age 12, levodopa-responsive severe akinetic-rigid parkinsonism, levodopa-induced motor fluctuations and dyskinesias, severe visual hallucinations, and supranuclear vertical gaze paresis, but no pyramidal deficit nor dementia. Brain CT scan showed moderate diffuse atrophy. Furthermore, two Italian cases with YOPD without atypical features carried a novel missense mutation (Thr12Met, Gly533Arg) in single heterozygous state.
CONCLUSIONS: We confirm that ATP13A2 homozygous mutations are associated with human parkinsonism, and expand the associated genotypic and clinical spectrum, by describing a homozygous missense mutation in this gene in a patient with a phenotype milder than that initially associated with ATP13A2 mutations (Kufor-Rakeb syndrome). Our data also suggest that ATP13A2 single heterozygous mutations might be etiologically relevant for patients with YOPD and further studies of this gene in Parkinson disease are warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485642     DOI: 10.1212/01.wnl.0000260963.08711.08

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  114 in total

1.  Developmental exposure to organophosphates triggers transcriptional changes in genes associated with Parkinson's disease in vitro and in vivo.

Authors:  Theodore A Slotkin; Frederic J Seidler
Journal:  Brain Res Bull       Date:  2011-09-28       Impact factor: 4.077

Review 2.  The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Authors:  Arash Velayati; W Haung Yu; Ellen Sidransky
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

Review 3.  Pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Cinzia Maria Bellettato; Maurizio Scarpa
Journal:  J Inherit Metab Dis       Date:  2010-04-29       Impact factor: 4.982

4.  Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration.

Authors:  Benjamin Dehay; Alfredo Ramirez; Marta Martinez-Vicente; Celine Perier; Marie-Hélène Canron; Evelyne Doudnikoff; Anne Vital; Miquel Vila; Christine Klein; Erwan Bezard
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-30       Impact factor: 11.205

5.  Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity.

Authors:  Marija Usenovic; Adam L Knight; Arpita Ray; Victoria Wong; Kevin R Brown; Guy A Caldwell; Kim A Caldwell; Igor Stagljar; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2012-05-29       Impact factor: 6.150

Review 6.  Genetics of neurodegeneration with brain iron accumulation.

Authors:  Allison Gregory; Susan J Hayflick
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

7.  Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Andrew Ferree; Katelyn Smith; Eugenio Barone; Marzia Perluigi; Raffaella Coccia; William Pierce; Jian Cai; Cesare Mancuso; Rachel Squillace; Manfred Wiengele; Isabella Dalle-Donne; Benjamin Wolozin; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-03-20       Impact factor: 8.401

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 9.  Lysosomal impairment in Parkinson's disease.

Authors:  Benjamin Dehay; Marta Martinez-Vicente; Guy A Caldwell; Kim A Caldwell; Zhenyue Yue; Mark R Cookson; Christine Klein; Miquel Vila; Erwan Bezard
Journal:  Mov Disord       Date:  2013-04-11       Impact factor: 10.338

Review 10.  Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease.

Authors:  Daniel J Colacurcio; Ralph A Nixon
Journal:  Ageing Res Rev       Date:  2016-05-16       Impact factor: 10.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.